- Poster presentation
- Open Access
Treatment of osteogenesis imperfecta with intravenous pamidronate in pediatric patients: comparison between a single-day infusion twice a year protocol with other regimens described in the literature
Pediatric Rheumatology volume 6, Article number: P133 (2008)
In 1995 our institution developed a protocol to treat children with pamidronate. Several protocols have been published to treat osteogenesis imperfecta (OI) in the last decades. Objectives: to review the usefulness of our protocol in OI and to compare it with published protocols.
Materials and methods
Retrospective review of OI patients treated with pamidronate from 1995 to 2006 in our centre. Inclusion criteria: OI < 18 years with z-score < -2.5, fractures and z < -1 or documented bone pain with z < -1. Treatment: 60 mg or 30 mg (in prepubescents) of pamidronate every six months in a single dose.
Despite a lower increase in z-score in our serie, the clinical efficacy is similar to other protocols. There is a tendency towards greater gain in Z-score as the annual dosage increases.
Glorieux FH: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. The New England Journal of Medicine. 1998, 339: 947-52. 10.1056/NEJM199810013391402.
Arikoski P: Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone. 2004, 34: 539-46. 10.1016/j.bone.2003.11.019.
About this article
Cite this article
Ricart, S., Anton, J., del Rio, M. et al. Treatment of osteogenesis imperfecta with intravenous pamidronate in pediatric patients: comparison between a single-day infusion twice a year protocol with other regimens described in the literature. Pediatr Rheumatol 6, P133 (2008) doi:10.1186/1546-0096-6-S1-P133
- Public Health
- Single Dose
- Pediatric Patient
- Average Length
- Clinical Efficacy